On the Record · Fresenius Medical Care
Fresenius Medical Care acquisitions, on the record
The businesses Fresenius Medical Care bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
National Cardiovascular Partners (NCP)Word for word“In December 2023, we completed the divestiture of National Cardiovascular Partners (NCP), comprising 21 facilities providing outpatient cardiac catheterization and vascular laboratory services, which were previously included in the Care Delivery segment of our U.S. health care service business.” 20-F for 2023 | divestiture | In December 2023 | — |
Cura Day Hospitals Group (Cura)Word for word“While we are currently the majority stakeholder in Cura Day Hospitals Group (Cura), a leading operator of day/short-stay hospitals in Australia, on January 8, 2024 we announced that an agreement has been signed to divest Cura to global alternative asset manager ICG and a consortium of health care professionals, subject to regulatory approval.” 20-F for 2023 | agreed divestiture | On January 8, 2024 | — |
Argentinian businessWord for word“In December 2023, we completed our exit from our Argentinian business and concluded the sale of National Cardiovascular Partners (NCP), including 21 facilities providing outpatient cardiac catheterization and vascular laboratory services, which were included in the Care Delivery business in the U.S.” 20-F for 2023 | divestiture | In December 2023 | — |
Clinic network in Sub-Saharan AfricaWord for word“As part of the strategic realignment of our product portfolio, we announced the divestment of our clinic network in Sub-Saharan Africa and sold our clinics in Hungary.” 20-F for 2023 | divestiture | — | — |
Clinics in HungaryWord for word“As part of the strategic realignment of our product portfolio, we announced the divestment of our clinic network in Sub-Saharan Africa and sold our clinics in Hungary.” 20-F for 2023 | divestiture | — | — |
W.R. Grace & Co. (Fresenius Worldwide Dialysis contributed by Fresenius SE)Word for word“On September 30, 1996, we completed a series of transactions to consummate an Agreement and Plan of Reorganization entered into on February 4, 1996 by Fresenius SE (then Fresenius AG) and W.R. Grace & Co. which we refer to as the “Merger” elsewhere in this report.” 20-F for 2023 | merger | On September 30, 1996 | — |
NxStage Medical, Inc. (NxStage)Word for word“In 2019, we completed our acquisition of NxStage Medical, Inc. (NxStage), which broadens our offerings of home hemodialysis treatment options.” 20-F for 2023 | acquisition | In 2019 | — |
Xenios AGWord for word“In December 2016, we acquired Xenios AG, a company focusing on products for extracorporeal heart and lung support for patients with severe heart and lung failure, in particular for the indications of severe acute respiratory distress syndrome, acute exacerbations of chronic obstructive pulmonary disease and cardiogenic shock.” 20-F for 2023 | acquisition | In December 2016 | — |
service businesses in Chile, Ecuador, Sub-Saharan Africa, Türkiye, Guatemala, Curacao, Peru, Colombia and the Cura Day Hospitals Group in AustraliaWord for word“Additionally during 2024, we divested our service businesses in Chile, Ecuador, Sub-Saharan Africa, Türkiye, Guatemala, Curacao, Peru, Colombia and the Cura Day Hospitals Group in Australia, and the Company's management committed to a plan to sell our renal dialysis clinic facilities and/or networks in Brazil, our business in Kazakhstan and select assets of the Company's wholly owned Spectra Laboratories, all in connection with the Legacy Portfolio Optimization plan.” 20-F for 2024 | divestiture | during 2024 | — |
renal dialysis clinic facilities and/or networks in Brazil, business in Kazakhstan, and select assets of Spectra LaboratoriesWord for word“Additionally during 2024, we divested our service businesses in Chile, Ecuador, Sub-Saharan Africa, Türkiye, Guatemala, Curacao, Peru, Colombia and the Cura Day Hospitals Group in Australia, and the Company's management committed to a plan to sell our renal dialysis clinic facilities and/or networks in Brazil, our business in Kazakhstan and select assets of the Company's wholly owned Spectra Laboratories, all in connection with the Legacy Portfolio Optimization plan.” 20-F for 2024 | agreed divestiture | — | — |
subsidiaries in Sub-Saharan Africa, Türkiye and the Cura Day Hospitals Group in AustraliaWord for word“In connection with our Legacy Portfolio Optimization program in our Care Delivery segment, we signed or closed divestments of our activities in all our Latin American markets and we successfully closed divestments of subsidiaries in Sub-Saharan Africa, Türkiye and the Cura Day Hospitals Group in Australia in 2024.” 20-F for 2024 | divestiture | in 2024 | — |
activities in all Latin American marketsWord for word“In connection with our Legacy Portfolio Optimization program in our Care Delivery segment, we signed or closed divestments of our activities in all our Latin American markets and we successfully closed divestments of subsidiaries in Sub-Saharan Africa, Türkiye and the Cura Day Hospitals Group in Australia in 2024.” 20-F for 2024 | agreed divestiture | — | — |
select laboratory and testing assets of Spectra Laboratories (to Quest Diagnostics Inc.)Word for word“In February 2025, Fresenius Medical Care announced the divestment of select laboratory and testing assets to Quest Diagnostics Inc.” 20-F for 2025 | divestiture | — | — |
renal dialysis clinic facilities in Brazil, Kazakhstan, and Malaysia and select assets of Spectra LaboratoriesWord for word“Additionally during 2025, we divested our renal dialysis clinic facilities in Brazil, Kazakhstan, and Malaysia and select assets of our wholly owned Spectra Laboratories while in 2024 we divested our service businesses in Chile, Ecuador, Sub-Saharan Africa, Türkiye, Guatemala, Curacao, Peru, Colombia, and the Cura Day Hospitals Group in Australia, all in connection with the Legacy Portfolio Optimization plan.” 20-F for 2025 | divestiture | during 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | −$577.6 million | $648.6 million |
Read from Fresenius Medical Care’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.